PERINATAL NEUROLOGICAL DISORDERS
Ischemic-hypoxic encephalopathy (IHE) is a neurological condition with high mortality and long-term complications. The damage is caused by conditions that alter the blood circulation and oxygenation of nervous tissue, consequent deprivation of energy sources, and cell death in the affected region.
Due to its potential for neuroprotection and neuroregeneration, stem cell transplantation has emerged in recent years as a promising therapeutic alternative to improve the performance of various components of cerebral palsy, accompanied by conventional rehabilitation programs.
IHE can cause hearing and vision loss, developmental delay, cerebral palsy, and epilepsy. Current treatments for IHE are limited and often unsuccessful. However, stem cell transplantation offers a potential new treatment option that shows promise for patients with IHE.
If you or a loved one has been diagnosed with IHE, talk to your doctor about the possibility of stem cell transplantation. This emerging treatment option may offer hope for a better outcome.
The gathering of sufficient evidence of the safety and efficacy of stem cells in animal models of IHE (3,4) made it possible to undertake the corresponding safety/efficacy clinical trials. Although the evidence in humans is still limited, fundamental studies of the way stem cells act in the injured nervous system, and the extensive demonstration of their safety justifies optimism about the benefits of stem cells in IHE and other neonatal disorders, such as bronchopulmonary dysplasia and intraventricular hemorrhage (5-8).
CEREBRAL PALSY
Due to its potential for neuroprotection and neuroregeneration, stem cell transplantation has emerged in recent years as a promising therapeutic alternative to improve the performance of various components of cerebral palsy, accompanied by conventional rehabilitation programs. Different clinical studies (case series, controlled clinical trials, and meta-analyses), which included hundreds of patients between 6 months and 20 years of age, have confirmed the safety and efficacy of several types of stem cells (9-17). Although the results of such studies are not unanimous, most have reported positive responses in cognition, language, self-care, motor function, social adaptability, and overall quality of life; adverse events have been minimal and temporary.
REFERENCES
1. Li F, Zhang K, Liu H, Yang T, Xiao DJ, Wang YS. The neuroprotective effect of mesenchymal stem cells is mediated through inhibition of apoptosis in hypoxic ischemic injury. World J Pediatr. 2019. doi: 10.1007/s12519-019-00310-x.
2. Xu J, Feng Z, Wang X, Xiong Y, Wang L, Ye L, et al. hUC-MSCs Exert a Neuroprotective Effect via Anti-apoptotic Mechanisms in a Neonatal HIE Rat Model. Cell Transplant. 2019;28(12):1552-1559. doi: 10.1177/0963689719874769.
3. Thomi G, Joerger-Messerli M, Haesler V, Muri L, Surbek D, Schoeberlein A. Intranasally Administered Exosomes from Umbilical Cord Stem Cells Have Preventive Neuroprotective Effects and Contribute to Functional Recovery after Perinatal Brain Injury. Cells. 2019;8(8). pii: E855. doi: 10.3390/cells8080855.
4. Kitase Y, Sato Y, Ueda K, Suzuki T, Mikrogeorgiou A, Sugiyama Y, et al. A Novel Treatment with Stem Cells from Human Exfoliated Deciduous Teeth for Hypoxic-Ischemic Encephalopathy in Neonatal Rats. Stem Cells Dev. 2020;29(2):63-74. doi: 10.1089/scd.2019.0221.
5. Xie B, Gu P, Wang W, Dong C, Zhang L, Zhang J, et al. Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy. Am J Transl Res. 2016 Jul 15;8(7):3241-50.
6. Kabataş S, Civelek E, İnci Ç, Yalçınkaya EY, Günel G, Kır G, et al. Wharton’s Jelly-Derived Mesenchymal Stem Cell Transplantation in a Patient with Hypoxic-Ischemic Encephalopathy: A Pilot Study. Cell Transplant. 2018;27(10):1425-1433. doi: 10.1177/0963689718786692.
7. McDonald CA, Djuliannisaa Z, Petraki M, Paton MCB, Penny TR, Sutherland AE, et al. Intranasal Delivery of Mesenchymal Stromal Cells Protects against Neonatal Hypoxic-Ischemic Brain Injury. Int J Mol Sci. 2019;20(10). pii: E2449. doi: 10.3390/ijms20102449.
8. Ahn SY, Park WS, Sung SI, Chang YS. Mesenchymal stem cell therapy for intractable neonatal disorders. Pediatr Neonatol. 2020:S1875-9572(20)30198-4. doi: 10.1016/j.pedneo.2020.11.007. Epub ahead of print. PMID: 33485822.
9. Novak I, Walker K, Hunt RW, Wallace EM, Fahey M, Badawi N. Concise Review: Stem Cell Interventions for People With Cerebral Palsy: Systematic Review With Meta-Analysis. Stem Cells Transl Med. 2016;5(8):1014-25. doi:10.5966/sctm.2015-0372.
10. Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, et al. A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy. Cell Transplant. 2018;27(2):325-334. doi: 10.1177/0963689717729379.
11. Boruczkowski D, Zdolińska-Malinowska I. Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study. Stem Cells Int. 2019;2019:7402151. doi: 10.1155/2019/7402151.
12. Eggenberger S, Boucard C, Schoeberlein A, Guzman R, Limacher A, Surbek D, et al. Stem cell treatment and cerebral palsy: Systemic review and meta-analysis. World J Stem Cells. 2019;11(10):891-903. doi: 10.4252/wjsc.v11.i10.891.
13. Gu J, Huang L, Zhang C, Wang Y, Zhang R, Tu Z, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;11(1):43. doi: 10.1186/s13287-019-1545-x.
14. Lee FK, Lin YL, Wang PH. Mesenchymal stem cells and cerebral palsy. J Chin Med Assoc. 2020;83(4):323-324. doi: 10.1097/JCMA.0000000000000263.
15. Vankeshwaram V, Maheshwary A, Mohite D, Omole JA, Khan S. Is Stem Cell Therapy the New Savior for Cerebral Palsy Patients? A Review. Cureus. 2020;12(9):e10214. doi: 10.7759/cureus.10214.
16. Xie B, Chen M, Hu R, Han W, Ding S. Therapeutic Evidence of Human Mesenchymal Stem Cell Transplantation for Cerebral Palsy: A Meta-Analysis of Randomized Controlled Trials. Stem Cells Int. 2020;2020:5701920. doi: 10.1155/2020/5701920.
17. Shintaku H. Prevention and treatment of cerebral palsy with cord blood stem cells and cord-derived mesenchymal stem cells. Neural Regen Res. 2021;16(4):672-673. doi: 10.4103/1673-5374.293139.
New Patient?
Schedule your FREE consultation!
Receive a complimentary consultation with one of a our Stem Cell Therapy Experts and Regenerative Doctors.
Call +1 (302) 551-3530 or fill out the form and one of our specialists will contact you within 24 hours.
Book For A Patient Advocate Follow-Up
Stem cell therapy does not provide a guarantee and is not advertised as a treatment for any cures. This is similar to many other traditional medical treatments. A patient history review is required to determine eligibility and approval for stem cell therapy as an aid to the patient’s body towards supporting the body’s own healing process, if and when possible. All personal information provided is for internal and medical use only by our healthcare providers. Headquartered in Deleware, USA, REJUV, INC. is a resource company and network supplier for REJUVSTEM in Guadalajara and Cancun, Mexico. Rejuv, Inc. is not a stem cell therapy facility or surgical center. These advanced treatments have not yet been approved by the FDA, so they are not available in our office or in the United States. All cell therapies are carried out in Mexico, as regulated by the Ministry of Health, COFERPIS, and other local governments. All treatments are carried out within the legal and regulatory framework of the country in which the particular healthcare provider operates.
